CELEX Oncology Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
3
CELEX Oncology General Information
Description
Operator of a biotechnology platform intended to support the development of targeted cancer therapies. The company offers research-driven therapeutics based on long-term studies and biological understanding, enabling patients with complex tumors access to focused treatment approaches.
Contact Information
Website
www.celexoncology.comCorporate Office
- 101 New Cavendish Street
- 1st Floor South
- London W1W 6XH
- England, United Kingdom
Corporate Office
- 101 New Cavendish Street
- 1st Floor South
- London W1W 6XH
- England, United Kingdom
CELEX Oncology Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Accelerator/Incubator | 01-Sep-2025 | Completed | Generating Revenue | |||
| 3. Later Stage VC | 01-Jul-2025 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 14-Jun-2024 | $323K | Completed | Generating Revenue | ||
| 1. Seed Round | 19-May-2017 | $323K | $323K | Completed | Startup |
CELEX Oncology Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
CELEX Oncology Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
CELEX Oncology Patents
CELEX Oncology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025252860-A1 | Ranolazine enantiomer for use in cancer treatment | Pending | 04-Jun-2024 | ||
| AU-2024357729-A1 | Treatment of metastatic or invasive brain cancer | Pending | 12-Oct-2023 | ||
| EP-4791406-A1 | Treatment of metastatic or invasive brain cancer | Pending | 12-Oct-2023 | ||
| WO-2025078664-A1 | Treatment of metastatic or invasive brain cancer | Inactive | 12-Oct-2023 | ||
| JP-2020200336-A | Treatment of cancer/inhibition of metastasis | Pending | 27-Aug-2020 |
CELEX Oncology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
CELEX Oncology Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Grow London | Accelerator/Incubator | |||
| Namier Capital Partners | Venture Capital | Minority | ||
| EIT Health | Accelerator/Incubator |
CELEX Oncology FAQs
-
When was CELEX Oncology founded?
CELEX Oncology was founded in 2016.
-
Where is CELEX Oncology headquartered?
CELEX Oncology is headquartered in London, United Kingdom.
-
What is the size of CELEX Oncology?
CELEX Oncology has 9 total employees.
-
What industry is CELEX Oncology in?
CELEX Oncology’s primary industry is Drug Discovery.
-
Is CELEX Oncology a private or public company?
CELEX Oncology is a Private company.
-
What is CELEX Oncology’s current revenue?
The current revenue for CELEX Oncology is .
-
How much funding has CELEX Oncology raised over time?
CELEX Oncology has raised $323K.
-
Who are CELEX Oncology’s investors?
Grow London, Namier Capital Partners, and EIT Health have invested in CELEX Oncology.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
